|Day Low/High||19.73 / 20.25|
|52 Wk Low/High||12.25 / 33.16|
Investors in Depomed Inc saw new options become available today, for the January 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DEPO options chain for the new January 2017 contracts and identified one put and one call contract of particular interest.
Despite a win in court over its patents and a deal with activist investors, Depomed shares dropped after it gave a reduced guidance for 2016 revenues.
Here are Tuesday's top research calls, including downgrades for Bank of America, Depomed, Hertz and AT&T.
The pain medication maker struck a deal with the fund managed by insurgent Jeff Smith to install a minority-slate of three dissident directors onto its board.
Increased chance for company's sale presents activist campaign with a steeper climb.
A New Jersey District Court has ruled in favor of Depomed's (DEPO) patents for its Nucynta drug franchise.
Investors in Depomed Inc saw new options begin trading this week, for the November 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DEPO options chain for the new November 18th contracts and identified one put and one call contract of particular interest.
The pharmaceutical company is reportedly up for sale after being dogged by Starboard Value for months, and could go for up to $41 million.
Sets November 15, 2016 as the Date for the Special Meeting and Believes Depomed Has Notified Broadridge of a September 27, 2016 Record Date
Depomed Shareholders Not Required to Take Action at This Time
Wall Street closed out a volatile week with slight losses as the Federal Reserve stays in focus.
Stocks hold lower on Friday as crude oil selloff pressures the energy sector and nerves over next week's Federal Reserve meeting peak.
Stocks fall on Friday as Wall Street eagerly awaits next week's meeting of the Federal Reserve.
Depomed (DEPO) stock was spiking on Friday morning as the company is reportedly preparing to explore a sale.
The buyer's CEO said it will look at both large acquisitions and Phase 2 and pre-approved assets in the wake of the $800 million purchase of the maker of Procysbi.
Perrigo is the second drug company that the activist has targeted in recent months after it rejected an unsolicited bid.
Horizon says the $800 million offer will bolster its rare disease business and its operations outside the U.S..
These four stocks are looking strong technically, either breaking out or approaching breakout levels.
The most recent short interest data has been released for the 08/15/2016 settlement date, which shows a 1,640,757 share decrease in total short interest for Depomed Inc , to 11,618,047, a decrease of 12.37% since 07/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.